DK3844147T3 - Forbindelser - Google Patents

Forbindelser Download PDF

Info

Publication number
DK3844147T3
DK3844147T3 DK20816376.6T DK20816376T DK3844147T3 DK 3844147 T3 DK3844147 T3 DK 3844147T3 DK 20816376 T DK20816376 T DK 20816376T DK 3844147 T3 DK3844147 T3 DK 3844147T3
Authority
DK
Denmark
Prior art keywords
connections
Prior art date
Application number
DK20816376.6T
Other languages
English (en)
Inventor
Peter Rands
George Knight
Richard Chubb
Derek Londesbrough
Tiffanie Benway
Zelah Joel
Original Assignee
Small Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1916210.6A external-priority patent/GB201916210D0/en
Priority claimed from GBGB1917320.2A external-priority patent/GB201917320D0/en
Priority claimed from GB2008303.6A external-priority patent/GB2585978B/en
Application filed by Small Pharma Ltd filed Critical Small Pharma Ltd
Application granted granted Critical
Publication of DK3844147T3 publication Critical patent/DK3844147T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16Tryptamines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK20816376.6T 2019-11-07 2020-11-09 Forbindelser DK3844147T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1916210.6A GB201916210D0 (en) 2019-11-07 2019-11-07 High purity tryptamines and methods of synthesis thereof
GBGB1917320.2A GB201917320D0 (en) 2019-11-28 2019-11-28 Novel compounds
GB2008303.6A GB2585978B (en) 2019-06-03 2020-06-02 Therapeutic compositions
PCT/EP2020/081502 WO2021089872A1 (en) 2019-11-07 2020-11-09 Compounds

Publications (1)

Publication Number Publication Date
DK3844147T3 true DK3844147T3 (da) 2022-07-04

Family

ID=75849570

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20816376.6T DK3844147T3 (da) 2019-11-07 2020-11-09 Forbindelser

Country Status (18)

Country Link
US (5) US11643390B2 (da)
EP (3) EP3844147B1 (da)
JP (3) JP7423131B2 (da)
KR (2) KR20230142817A (da)
CN (2) CN114829341B (da)
AU (2) AU2020378647B2 (da)
BR (1) BR112022008919A2 (da)
CA (2) CA3160334C (da)
DK (1) DK3844147T3 (da)
ES (2) ES2920681T3 (da)
HR (2) HRP20230281T1 (da)
HU (2) HUE059403T2 (da)
IL (2) IL292753B2 (da)
MX (1) MX2022005399A (da)
NZ (1) NZ788543A (da)
PL (2) PL3873883T3 (da)
PT (2) PT3873883T (da)
WO (2) WO2021089872A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
EP3844147B1 (en) 2019-11-07 2022-04-06 Small Pharma Ltd Compounds
JP2023513680A (ja) 2020-02-04 2023-04-03 マインドセット ファーマ インコーポレイテッド 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体
US11332441B2 (en) * 2020-03-23 2022-05-17 Caamtech, Inc. Crystalline N-methyl tryptamine derivatives
US20230219889A1 (en) 2020-05-19 2023-07-13 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
CA3179161C (en) * 2020-06-02 2023-10-31 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
WO2021116503A2 (en) * 2020-06-02 2021-06-17 Small Pharma Ltd Deuterated compounds
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
KR20230024378A (ko) 2020-06-12 2023-02-20 벡클리 싸이테크 리미티드 5-메톡시-n, n-디메틸트립타민의 벤조에이트 염을 포함하는 조성물
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
MX2023014620A (es) 2021-06-09 2024-01-30 Atai Therapeutics Inc Nuevos profarmacos y conjugados de dimetiltriptamina.
EP4122916A1 (en) * 2021-07-22 2023-01-25 GH Research Ireland Limited Method for preparing an organic compound
JP2024524775A (ja) * 2021-07-22 2024-07-05 ジーエイチ・リサーチ・アイルランド・リミテッド トリプタミン誘導体の調製方法
US11697638B2 (en) * 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
EP4159192A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders
IL312859A (en) 2021-11-18 2024-07-01 Cybin Uk Ltd Injectable and inhaled formulations
WO2023108174A1 (en) * 2021-12-10 2023-06-15 Terran Biosciences, Inc. Analogs of 6-methoxy- n, n-dimethyltryptamine
AU2022425541A1 (en) 2021-12-30 2024-06-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
WO2023147423A1 (en) * 2022-01-28 2023-08-03 Miralogx Llc Anxiolytic compounds, pharmaceutical compositions, and methods of treating anxiety and other disorders
US20230202978A1 (en) 2022-03-04 2023-06-29 Reset Pharmaceuticals, Inc. Co-crystal or salt
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
US20240101514A1 (en) * 2022-08-19 2024-03-28 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
WO2024079314A1 (en) 2022-10-13 2024-04-18 Cybin Uk Ltd Method of administration of a parenteral formulation comprising a psychedelic agent
WO2024119075A1 (en) * 2022-12-01 2024-06-06 ATAI Life Sciences AG Crystalline forms of n,n-dimethyltryptamine and methods of using the same
WO2024156713A1 (en) 2023-01-23 2024-08-02 Cybin Uk Ltd Treatment of psychiatric or neurological disorders by parenteral administration of a single, effective parenteral dose of a short-acting psychedelic agent

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4336378A (en) 1980-04-10 1982-06-22 Sandoz, Inc. Isoxazolyl indolamines
JPH06508354A (ja) * 1991-06-21 1994-09-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー トリプタミン類似体、その合成法およびその5−ht↓1様または5−ht↓2受容体作用物質としての使用
US6376531B1 (en) 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
JP2003535884A (ja) 2000-06-16 2003-12-02 スカイファーマ・カナダ・インコーポレーテッド プロポフォールの改善された注射可能な分散物
WO2004085392A1 (en) 2003-03-25 2004-10-07 Faust Pharmaceuticals Melatonin derivatives and their use for treating neurological dysfunctions
CA2666149A1 (en) 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
WO2008071455A1 (en) 2006-12-15 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
CZ302424B6 (cs) * 2007-06-13 2011-05-11 Zentiva, A. S. Zpusob prípravy almotriptanu o vysoké cistote
US20090041800A1 (en) * 2007-08-06 2009-02-12 Synosia Therapeutics, Inc. Methods for Treating Dependence
US20090076121A1 (en) 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched sumatriptan
EP2209380A4 (en) 2007-10-09 2011-09-14 Mark T Hamann METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF
CN108299400B (zh) * 2013-03-14 2021-02-19 达特神经科学(开曼)有限公司 作为pde4抑制剂的取代的吡啶和取代的吡嗪化合物
US10336703B2 (en) 2015-05-12 2019-07-02 Council Of Scientific And Industrial Research Process for the synthesis of ivacaftor and related compounds
US20200030309A1 (en) * 2016-09-29 2020-01-30 The Regents Of The University Of California Compounds for increasing neural plasticity
CN110740728A (zh) 2017-02-09 2020-01-31 卡马技术有限责任公司 包含裸头草碱衍生物的组合物和方法
WO2018195455A1 (en) 2017-04-20 2018-10-25 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US11723894B2 (en) * 2017-10-26 2023-08-15 Terran Biosciences, Inc. Combination product for the treatment of neurological and/or psychiatric disorders
WO2019089902A1 (en) 2017-11-01 2019-05-09 Drexel University Compounds, compositions, and methods for treating diseases
US20220031662A1 (en) 2019-02-22 2022-02-03 GH Research Ireland Limited Compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in treating mental disorders
CR20210437A (es) 2019-02-22 2021-11-02 Gh Res Ireland Limited 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión
EP3931189A4 (en) 2019-02-27 2022-11-30 The Regents Of The University Of California AZEPINO-INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS
JP2022523774A (ja) * 2019-02-27 2022-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 脳障害を治療するためのn-置換インドール及び他の複素環化合物
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
EP3844147B1 (en) 2019-11-07 2022-04-06 Small Pharma Ltd Compounds
CN111072492A (zh) * 2019-11-29 2020-04-28 浙江工业大学 一种合成3,4-二氯-2-氨基-5-氟联苯的方法
JP2023513680A (ja) 2020-02-04 2023-04-03 マインドセット ファーマ インコーポレイテッド 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体
US20230219889A1 (en) 2020-05-19 2023-07-13 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
WO2021234608A1 (en) 2020-05-19 2021-11-25 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
WO2021116503A2 (en) 2020-06-02 2021-06-17 Small Pharma Ltd Deuterated compounds
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
GB202008961D0 (en) 2020-06-12 2020-07-29 Beckley Psytech Ltd Pharmaceutical composition
US20220040150A1 (en) 2020-08-05 2022-02-10 Universitatsspital Basel Intravenous dmt administration method for dmt-assisted psychotherapy
US20220062237A1 (en) 2020-08-28 2022-03-03 Small Pharma Ltd Injectable formulation
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
AU2021334933B2 (en) 2020-08-28 2023-01-19 Cybin Uk Ltd Injectable formulation
AU2021354006A1 (en) 2020-10-02 2023-03-02 Cybin Irl Limited Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
US11000534B1 (en) 2020-10-08 2021-05-11 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof
US20240016782A1 (en) 2020-12-01 2024-01-18 Small Pharma Ltd. Inhalable formulations
EP4275753A3 (en) 2020-12-01 2023-12-27 Small Pharma Ltd Deuterated or partially deuterated n,n-dimethyltryptamine compounds
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
US20230149293A1 (en) 2021-11-18 2023-05-18 Small Pharma Ltd. Injectable and inhalable formulations

Also Published As

Publication number Publication date
JP2022546635A (ja) 2022-11-04
CN114829340A (zh) 2022-07-29
AU2020381103B2 (en) 2022-08-11
CN114829341A (zh) 2022-07-29
US20240217929A1 (en) 2024-07-04
CA3160337C (en) 2023-08-29
MX2022005399A (es) 2022-07-05
IL292754A (en) 2022-07-01
WO2021089872A1 (en) 2021-05-14
IL292753B1 (en) 2023-09-01
HUE061482T2 (hu) 2023-07-28
PL3873883T3 (pl) 2023-05-08
CA3160337A1 (en) 2021-05-14
BR112022008919A2 (pt) 2022-08-09
JP7422473B2 (ja) 2024-01-26
WO2021089873A1 (en) 2021-05-14
KR20220082092A (ko) 2022-06-16
EP3873883A1 (en) 2021-09-08
NZ788543A (en) 2022-10-28
AU2020378647B2 (en) 2023-06-15
IL292753B2 (en) 2024-01-01
IL292753A (en) 2022-07-01
ES2920681T3 (es) 2022-08-08
US11643390B2 (en) 2023-05-09
PT3873883T (pt) 2023-03-24
JP2024028798A (ja) 2024-03-05
US12084417B2 (en) 2024-09-10
AU2020378647A1 (en) 2022-06-09
US20230167056A1 (en) 2023-06-01
CA3160334C (en) 2024-04-30
JP7423131B2 (ja) 2024-01-29
ES2940811T3 (es) 2023-05-11
CA3160334A1 (en) 2021-05-14
CN114829340B (zh) 2023-12-12
EP3873883B1 (en) 2022-12-21
JP2023500532A (ja) 2023-01-06
US20210395201A1 (en) 2021-12-23
EP4180037A1 (en) 2023-05-17
US11578039B2 (en) 2023-02-14
AU2020381103A1 (en) 2022-06-09
EP3844147B1 (en) 2022-04-06
PT3844147T (pt) 2022-07-04
US20230250059A1 (en) 2023-08-10
PL3844147T3 (pl) 2022-07-18
CN114829341B (zh) 2024-03-08
HUE059403T2 (hu) 2022-11-28
HRP20230281T1 (hr) 2023-04-28
KR20230142817A (ko) 2023-10-11
EP3844147A1 (en) 2021-07-07
US20220281818A1 (en) 2022-09-08
HRP20220797T1 (hr) 2022-10-14

Similar Documents

Publication Publication Date Title
DK3844147T3 (da) Forbindelser
DK3810602T3 (da) Forbindelser
DK3738452T3 (da) Fordamper
DK3810633T3 (da) Forbindelser
ES1243687Y (es) Salmorejo
IT201900020430A1 (it) Espositore
DE202019004111U8 (de) Weichenstellvorichtung
TH190914S (th) ขันโตก
TH190910S (th) ขันโตก
TH190911S (th) ขันโตก
DK3786413T3 (da) Rullejalousi
ES1235736Y (es) Alcoholimetro
ES1234309Y (es) Bolardo
UA40531S (uk) Електропила ланцюгова
UA40533S (uk) Електропила ланцюгова
UA40530S (uk) Електропила ланцюгова
UA40524S (uk) Вороток
UA40532S (uk) Електропила ланцюгова
UA40639S (uk) Мотоблок
UA40636S (uk) Мотоблок
ES1232841Y (es) Barbacoa plancha
UA40495S (uk) Мультиварка
UA40385S (uk) Сендвічмейкер
UA40386S (uk) Сендвічмейкер
UA40481S (uk) Сендвичмейкер